• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Analytical Tool - Protein Kinase Inhibitors in Oncology Product Image

Analytical Tool - Protein Kinase Inhibitors in Oncology

  • ID: 328323
  • March 2014
  • Region: Global
  • Bioseeker

Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors (PKIs) for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2014*

The READ MORE >

Note: Product cover images may vary from those shown

Strategic Outlook on Protein Kinase Inhibitors in Oncology

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 List of Contents

4.1 List of Boxes
4.2 List of Figures
4.3 List of Tables

5 Rationale for Development of Kinase Inhibitors in Oncology

6 Protein Kinase Targets - A Growing Family

6.1 Challenges in Protein Kinase Drug Discovery
6.1.1 Enabling Structure-Based Drug Design is the Key
6.1.2 Specific Kinase Inhibitors without Kinase Profiling?
6.2 Drugs according to Target
6.2.1 Cyclin-dependent Kinase Target Inhibitors
6.2.2 Aurora Kinase Target Inhibitors
6.2.3 Cell Cycle Checkpoint Target Controls Inhibitors
6.2.4 Tyrosine Kinase Receptor Inhibitors
6.2.5 Other Serine/Threonine Kinase Target Inhibitors
6.3 Dual or Multiple Kinase Inhibitor Analysis
6.3.1 Presentation of Drugs Targeting A to F Kinases
6.3.2 Presentation of Drugs Targeting G to T Kinases
6.4 Targets According to Indication
6.4.1 Breast Cancer
6.4.2 Prostate Cancer: What Cannot be Found in the ‘Groins’?
6.4.3 Lung Cancer: A Need for Improved Survival Rates
6.4.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but there are Others
6.4.5 Leukemia: Show Me the Power of PKI
6.4.6 Melanoma
6.4.7 Lymphoma: We Are In

7 Growing Competition in the Field

7.1 Big Pharma Outlook: The Race is On
7.1.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
7.1.2 AstraZeneca - Wheeling and Dealing
7.1.3 Pfizer’s Long Look at OSI Pharmaceuticals
7.1.4 GlaxoSmithKline Gains Momentum
7.2 Strategic Deals Creating Competitive Edge
7.2.1 Mergers
7.2.2 Astex - the PKI Switchboard
7.2.3 Big Pharma’s Darling

8 Current Protein Kinase Inhibitors in Therapy

8.1 Mechanism, Target and Developmental History
8.2 Approvals: Indications & Markets

9 Protein Kinase Inhibitors in Drug Development - A Progress Analysis

9.1 Progress Analysis - Breast Cancer
9.2 Progress Analysis - Prostate Cancer
9.3 Progress Analysis - Lung Cancer
9.4 Progress Analysis - Colorectal Cancer
9.5 Progress Analysis - Leukemia
9.6 Progress Analysis - Melanoma
9.7 Progress Analysis - Lymphoma

10 Selected Company profiles

11 Disclaimer

12 Drug Index

13 Company Index

4.1 List of Boxes

Box 1: The Power of Ambit’s Kinase Profiling
Box 2: Summary Terms of the Exelixis Transaction

4.2 List of Figures

Figure 1: Top 10 PKI Drug Developing Companies
Figure 2: Clinical Trial Distribution in Breast Cancer for PKI Drugs
Figure 3: Clinical Trial Distribution in Prostate Cancer for PKI Drugs
Figure 4: Clinical Trial Distribution in Lung Cancer for PKI Drugs
Figure 5: Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
Figure 6: Clinical Trial Distribution in Leukemia for PKI Drugs
Figure 7: Clinical Trial Distribution in Melanoma for PKI Drugs
Figure 8: Clinical Trial Distribution in Lymphoma for PKI Drugs

4.3 List of Tables

Table 1: Overview of Targets in Commercial Development
Table 2: Cyclin-dependent Kinase Targets in Development
Table 3: Aurora Kinase Targets in Development
Table 4: Cell Cycle Checkpoint Targets in Development
Table 5: Epidermal Growth Factor Receptor Targets in Development
Table 6: FMS-like tyrosine kinases and their Synonyms
Table 7: Fms-related Tyrosine Kinase Targets in Development
Table 8: Platelet-derived Growth Factor Receptor Targets in Development
Table 9: Kinase Insert Domain Targets in Development
Table 10: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
Table 11: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
Table 12: Serine/Threonine Kinase Inhibitors in Development
Table 13: Protein Kinase Targets in Clinical Trials for Breast Cancer
Table 14: Protein Kinase Targets in Clinical Trials for Prostate Cancer
Table 15: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 16: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
Table 17: Protein Kinase Targets in Clinical Trials for Leukemia
Table 18: Protein Kinase Targets in Clinical Trials for Melanoma
Table 19: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 20: Drugs in Therapy - Mechanism & Targets
Table 21: Current and Developmental History of PKI Drugs in Therapy
Table 22: Approvals: Indications & Markets
Table 23: Top 10 Drugs in Terms of Number of Clinical Trials
Table 24: List of Cancer Indications Targeted by Protein Kinase Inhibitors
Table 25: PKI Drugs in Development for Breast Cancer
Table 26: PKI Drugs in Development for Prostate Cancer
Table 27: PKI Drugs in Development for Lung Cancer
Table 28: PKI Drugs in Development for Colorectal Cancer
Table 29: PKI Drugs in Development for Leukemia
Table 30: PKI Drugs in Development for Melanoma
Table 31: PKI Drugs in Development for Lymphoma

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos